Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:22 PM
Ignite Modification Date:
2025-12-24 @ 10:22 PM
NCT ID:
NCT00004135
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed metastatic renal cell carcinoma or melanoma that is not potentially curable by surgery
* Evaluable disease or bidimensionally measurable disease on physical examination, chest x-ray, CT scan, or MRI
* Measurable disease by radiography must be reproducible
* Bony disease or effusions not measurable
* No active CNS disease currently receiving radiotherapy or steroids
* No effusion or ascites of more than 1 liter prior to drainage
* HLA 5/6 or 6/6 matched sibling donor available
* No known hypersensitivity to E. coli derived products
* No active infection
* No health condition that would preclude donation
PATIENT CHARACTERISTICS:
Age:
* 18 to 65
Performance status:
* CALGB 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Bilirubin no greater than 2.0 g/dL
* No active hepatitis
Renal:
* Creatinine no greater than 2.0 mg/dL OR
* Creatinine clearance greater than 50 mL/min
Cardiovascular:
* LVEF at least 50%
Pulmonary:
* DLCO at least 50% of predicted
Other:
* No active infection
* HIV negative
* No psychological problem that would preclude study compliance
* No known hypersensitivity to E. coli derived products
* Not pregnant or nursing
* Negative pregnancy test
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* At least 4 weeks since prior systemic chemotherapy
Endocrine therapy:
* See Disease Characteristics
Radiotherapy:
* See Disease Characteristics
* At least 4 weeks since prior radiotherapy
Surgery:
* See Disease Characteristics
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT00004135
Study Brief:
Protocol Section:
NCT00004135